CD274 and infantile convulsions and choreoathetosis: The combination of gemcitabine and cisplatin, along with anti-programmed cell death protein 1 (anti-PD-1, pembrolizumab)/PD-1 ligand (PD-L1, durvalumab) therapy, is currently being used as the first-line treatment for patients with advanced iCCA [12, 24].